<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03690739</url>
  </required_header>
  <id_info>
    <org_study_id>AGO-OVAR 2.32</org_study_id>
    <nct_id>NCT03690739</nct_id>
  </id_info>
  <brief_title>Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer</brief_title>
  <official_title>Trabectedin/PLD Versus Continuation of Platinum-based Chemo-therapy in Patients With Disease Stabilization and no Symptom Benefit Under Platinum-based Chemotherapy for Recurrent Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AGO Research GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AGO Research GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, prospective, randomized, controlled, parallel group, multi-center
      phase III trial to evaluate the Symptom Benefit Rate of trabectedin/PLD in patients with
      recurrent ovarian cancer who achieve a stabilization of disease after 3 cycles of
      platinum-based reinduction therapy and with no clinical benefit.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 330 patients will be randomized in a 1:1 ration to the treatments specified
      below:

      Arm A - Platinum-based chemotherapy according to investigator's discretion Arm B - Pegylated
      liposomal doxorubicin 30 mg/m² + Trabectedin 1.1 mg/m² (q3w)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 9, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptom Benefit Rate</measure>
    <time_frame>from Baseline to 8 or 9 weeks after randomization, assessed at each visit</time_frame>
    <description>Proportion of patients achieving a symptom benefit defined as an at least 10-point improvement according to EORTC QLQ-OV28; EORTC QLQ-OV28 is a questionnaire regarding Quality of Life specialized for Ovarian Cancer with points from 1 till 4 for each of the 28 questions (1=not at all, 2=a little, 3=quite a bit, 4=very much). Points will be summarized.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time until definitive deterioration (TUDD )</measure>
    <time_frame>from Baseline until 24 months after randomization, assessed up to 54 months at each visit</time_frame>
    <description>TUDD is defined as time from baseline until the first decrease in EORTC QLQ-C30 score ≥ 10 points (or 20 points) as compared at baseline; EORTC QLQ-C30 is a questionnaire regarding Quality of Life specialized for Cancer with points for each of the 30 questions (1=not at all, 2=a little, 3=quite a bit, 4=very much). Points will be summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>PFS is defined as time from randomization to disease progression according to RECIST v1.1, to death from any cause or to start of a new treatment (whichever occurs first), assessed up to 54 months</time_frame>
    <description>Progressive disease is based on investigator assessment using RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) rate at 6 months</measure>
    <time_frame>PFS is defined as time from randomization to disease progression according to RECIST v1.1, to death from any cause or to start of a new treatment (whichever occurs first) after six months</time_frame>
    <description>Progressive disease is based on investigator assessment using RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate (RR)</measure>
    <time_frame>from randomization until patients achieving complete response (CR) or partial response (PR) as best overall response, assessed up to 54 months</time_frame>
    <description>RR is based on investigator assessment using RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Health Status</measure>
    <time_frame>from baseline to end of treatment, assessed up to 54 months at each visit</time_frame>
    <description>based on Quality of Life; EORTC QLQ-C30 and EORTC QLQ-OV 28 are questionnaires for Quality of Life with points for each of the 30 or 28 questions (1=not at all, 2=a little, 3=quite a bit, 4=very much). Points will be summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>OS is defined as the time from randomization to death from any cause, assessed up to 54 months</time_frame>
    <description>regular patient contact during the trila regarding life status</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Recurrent Ovarian Carcinoma</condition>
  <arm_group>
    <arm_group_label>platinum-based chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>According to the investigator's discretion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLD + Trabectedin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PLD 30 mg/m² + Trabectedin 1.1 mg/m² q21</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Administration according to investigator's discretion</description>
    <arm_group_label>platinum-based chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Administration according to investigator's discretion</description>
    <arm_group_label>platinum-based chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Administration according to investigator's discretion</description>
    <arm_group_label>platinum-based chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLD</intervention_name>
    <description>Administration according to investigator's discretion</description>
    <arm_group_label>platinum-based chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Administration according to investigator's discretion</description>
    <arm_group_label>platinum-based chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLD</intervention_name>
    <description>Administration 30 mg/m² q21</description>
    <arm_group_label>PLD + Trabectedin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trabectedin</intervention_name>
    <description>Administration 1.1 mg/m² q21</description>
    <arm_group_label>PLD + Trabectedin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Administration according to investigator's discretion</description>
    <arm_group_label>platinum-based chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Females aged ≥ 18 years at time of signing informed consent form.

          2. Histologically proven diagnosis of cancer of the ovary, the fallopian tube or primary
             peritoneal cancer.

          3. Measurable or non-measurable disease (according RECIST v1.1) or CA-125 assessable
             disease (according GCIG criteria) or histologically proven diagnosis of relapse.

          4. Platinum-treatment free interval (TFIp) &gt; 6 months prior to cycle 1 day 1 of
             reinduction therapy.

          5. Disease stabilization without remission or progression ac-cording to RECIST or GCIG
             criteria after three cycles of platinum-based chemotherapy for recurrent disease.

          6. Symptomatic disease at time of baseline abdominal/GI symptom scale score &gt;15 (EORTC
             QLQ-OV28)

          7. Completion of EORTC QLQ-OV28 at Baseline within 7 days prior to treatment start.

          8. Patients should have received previously a taxane derivative.

          9. ECOG performance status ≤ 2.

         10. Life expectancy of at least 12 weeks.

         11. Adequate bone marrow, renal and hepatic function defined as:

               -  Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L

               -  Platelet count ≥ 100 x 10^9/L

               -  Hemoglobin ≥ 9.0 g/dL

               -  Serum creatinine ≤1.5 mg/dL (≤ 132.6 µmol/L) or creatinine clearance ≥ 60 mL/min

               -  Creatine phosphokinase (CPK) ≤ 2.5 x ULN

               -  Serum aspartate aminotransferase (AST, SGOT) or alanine aminotransferase (ALT,
                  SGPT) ≤ 2.5 x ULN (≤ 5 x ULN in the presence of liver metastases)

               -  Alkaline phosphatase (ALP) ≤ 2.5 ULN

               -  Serum bilirubin ≤ ULN

               -  Albumin ≥ 25 g/l

         12. Participation in an informed consent discussion with the appropriate trial-related
             health care representative, full understanding of the implications and constraints of
             the protocol, and provision of written informed consent prior to the commencement of
             the trial-related procedures.

         13. Geographically accessibility for treatment and follow-up.

         14. For women of childbearing potential (WOCBP): agreement to remain abstinent (refrain
             from heterosexual inter-course) or use a contraceptive method with a failure rate of &lt;
             1 per-centage per year during the treatment period and for at least six months after
             administration of the last dose of chemo-therapy. A woman is considered to be of
             childbearing po-tential if she is postmenarcheal, has not reached a post-menopausal
             state (≥ 12 continuous months of amenorrhea with no identified cause other than
             menopause), and has not undergone surgical sterilization (removal of ovaries,
             fal-lopian tubes, and/or uterus). Examples of contraceptive methods with a failure
             rate of &lt; 1 percentage per year in-clude but are not limited to bilateral tubal
             ligation and/or oc-clusion, male sterilization, and intrauterine devices, and nor-mal
             and low dose combined oral pill plus male condom or Cerazette (desogestrel) plus male
             condom. Cerazette is currently the only highly efficacious progesterone based pill.
             The reliability of sexual abstinence should be evaluated in relation to the duration
             of the clinical trial and the preferred and usual lifestyle of the patient. Periodic
             abstinence (e.g., calendar, ovulation, symptothermal, or postovulation meth-ods) and
             withdrawal are not acceptable methods of contra-ception.

        Exclusion Criteria:

          1. Ovarian tumors of low malignant potential (e.g. borderline tumors).

          2. Non-epithelial ovarian or mixed epithelial/non epithelial tumors (e.g. mixed Müllerian
             tumors).

          3. Patients with an objective response in terms of a partial or complete remission or
             alternatively progressive disease ac-cording to RECIST or GCIG criteria after three
             cycles of platinum-based reinduction chemotherapy.

          4. Patients who have received previous radiotherapy for ovarian cancer.

          5. History of congestive heart failure (NYHA classification &gt; 2, even if medically
             con-trolled).

          6. History of myocardial infarction within the last six months (documented or by
             electrocardiogram).

          7. History of atrial or ventricular arrhythmias.

          8. Impaired liver function, hyperbilirubinemia, Serum creatinine &gt;1.5 mg/dL or &gt; 132.6
             μmol/L or creatinine clearance &lt; 60 mL/min, left ventricular ejection fraction &lt; 45 %.

          9. Severe active or uncontrolled infection.

         10. Concurrent severe medical problems unrelated to malignancy, which would significantly
             limit full compliance with the trial or expose the patient to extreme risk or
             decreased life expectancy.

         11. Patients with known hypersensitivity to the active substance or their compounds
             related to trabectedin or PLD and patients with known hypersensitivity to one of
             active substances or one of their compounds used in platinum-based chemotherapy as
             described in the Summaries of Medicinal Products.

         12. Patients with potential risks according to contraindication, warnings or interactions
             of the used chemotherapeutic agents as stated in the SmPCs are not eligible for
             participation in this trial.

         13. Patients with contraindication regarding CT or MRI (only in case of contrast allergy)
             are excluded.

         14. Women of childbearing potential (WOCBP) not using highly effective contraceptive
             methods.

         15. Pregnancy or breast-feeding.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felix Hilpert, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Mammazentrum am Krankenhaus Jerusalem, Hamburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michaela Fredrich</last_name>
    <phone>+49 611 880 4670</phone>
    <email>mfredrich@ago-ovar.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinikum Aschaffenburg-Alzenau</name>
      <address>
        <city>Aschaffenburg</city>
        <state>Bayern</state>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hochtaunus-Kliniken</name>
      <address>
        <city>Bad Homburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sotzialstiftung Bamberg</name>
      <address>
        <city>Bamberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hans-Martin Enzinger</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Bergisch Gladbach</name>
      <address>
        <city>Bergisch Gladbach</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eva Egger</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis für Onkologie / Hämatologie</name>
      <address>
        <city>Bottrop</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Hannig</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Frauenärzte Casparistraße</name>
      <address>
        <city>Braunschweig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralf Lorenz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pauline Wimberger</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Evang. Kliniken Essen-Mitte</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Agaplesion Markus Krankenhaus</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Greifswald</name>
      <address>
        <city>Greifswald</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mammazentrum Hamburg am Krankenhaus Jerusalem</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felix Hilpert</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Itzehoe</name>
      <address>
        <city>Itzehoe</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ViDia Christliche Kliniken Karlsruhe</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Tomé</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Ludwigsburg</name>
      <address>
        <city>Ludwigsburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Katholisches Klinikum Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnd Hönig</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik Mannheim</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Memmingen</name>
      <address>
        <city>Memmingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Felix Flock</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kliniken des Landkreises Neumarkt</name>
      <address>
        <city>Neumarkt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Innere Medizin, Onkologie und Hämatologie</name>
      <address>
        <city>Oldenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claus-Henning Koehne</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Ernst von Bergmann</name>
      <address>
        <city>Potsdam</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dorothea Fischer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Agaplesion Diakonieklinikum Rotenburg</name>
      <address>
        <city>Rotenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tobias Hesse</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thüringen Kliniken &quot;Georgius Agricola&quot;</name>
      <address>
        <city>Saalfeld</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>g.Sund Gyn. Kompetenzzentrum</name>
      <address>
        <city>Stralsund</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carsten Hielscher</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kreiskrankenhaus &quot;Johann Kentmann&quot;</name>
      <address>
        <city>Torgau</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helios Dr. Horst Schmidt Kliniken</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Eichbaum</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 26, 2018</study_first_submitted>
  <study_first_submitted_qc>September 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2018</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Symptom Benefit</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Trabectedin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

